Business
Spectral Co-hosts Endotoxemia Scientific Session at SEPSIS 2007
Spectral Co-hosts Endotoxemia Scientific Session at SEPSIS 2007.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, Sept. 27 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today\nannounced the co-sponsorship with Toray Medical Company (Tokyo, Japan) of a\nkey scientific session at SEPSIS 2007, an International Symposium held at the\nInstitut Pasteur in Paris, France from September 26-29th, 2007. "Endotoxemia -\nDetection, Consequence and Intervention" will feature a panel of four thought\nleaders in the field of sepsis discussing the value of Spectral's EAA(TM)\nEndotoxin Activity Assay. The EAA(TM) is the only FDA cleared, whole blood\nassay for the detection of endotoxemia.\n\n\n"There is growing recognition of the role that exdotoxins play in the\nonset of Sepsis, as is reflected by the number of sessions at this symposium\nthat will address this topic," said Dr. Paul Walker, President and CEO of\nSpectral Diagnostics. "We are pleased to participate in SEPSIS 2007 as it\ngives us the opportunity to further demonstrate the utility of our EAA(TM)\nEndotoxin Activity Assay to a large group of clinicians who are focused on\ntreating patients with Sepsis."\n\n\nThe "Endotoxemia - Detection, Consequence and Intervention" scientific\nsession will take place on Friday, September 28, 2007 at the Institut Pasteur\nAuditorium at 16:30CEST and the panel will include International Sepsis Forum\nChair, Dr. John Marshall of St. Michael's Hospital in Toronto, Canada. For\nfurther information please visit: http://www.sepsisforum.org.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral technologies provide accurate and timely\ninformation to clinicians enabling the early initiation of appropriate and\ntargeted therapy. Current products include Spectral's FDA approved rapid\ndiagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid\ndiagnostic for sepsis (EAA(TM)), as well as a range of other biological\nreagents. Spectral is listed on TSX under the symbol SDI.\n\n\nForward-looking statement\n\n\nInformation in this news release that is not current or historical\nfactual information may constitute forward-looking information within the\nmeaning of securities laws. Implicit in this information, particularly in\nrespect of the future outlook of Spectral and anticipated events or results,\nare assumptions based ...